Alzheimer's Disease, Blood Biomarkers
Conditions
Brief summary
The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are: * to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.
Interventions
DIAGNOSTIC_TESTBlood biomarker
Blood biomarker
Sponsors
Peking University First Hospital
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age ≥ 50 years; * AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects; * Signed informed consent form.
Exclusion criteria
* The presence of other disorders that can cause cognitive impairment; * Unable to cooperate with the completion of cognitive assessment; * Refusal to draw blood.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the diagnostic accuracy of blood biomarkers of Aβ42, Aβ40, Aβ42/Aβ40, P-Tau181, P-Tau217, GFAP and NfL. | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the diagnostic accuracy of a comprehensive model combined with core blood biomarkers and clinical information. | 2 years |
Countries
China
Contacts
Primary ContactChen Zhang
Outcome results
None listed